Patient Characteristics and General Practitioners’ Advice to Stop Statins in Oldest-Old Patients: a Survey Study Across 30 Countries

ArticleAçık Erişim

Özet

Background: Statins are widely used to prevent cardiovascular disease (CVD). With advancing age, the risks of statins might outweigh the potential benefits. It is unclear which factors influence general practitioners’ (GPs) advice to stop statins in oldest-old patients. Objective: To investigate the influence of a history of CVD, statin-related side effects, frailty and short life expectancy, on GPs’ advice to stop statins in oldest-old patients. Design: We invited GPs to participate in this case-based survey. GPs were presented with 8 case vignettes describing patients > 80 years using a statin, and asked whether they would advise stopping statin treatment. Main Measures: Cases varied in history of CVD, statin-related side effects and frailty, with and without shortened life expectancy (< 1 year) in the context of metastatic, non-curable cancer. Odds ratios adjusted for GP characteristics (ORadj) were calculated for GPs’ advice to stop. Key Results: Two thousand two hundred fifty GPs from 30 countries participated (median response rate 36%). Overall, GPs advised stopping statin treatment in 46% (95%CI 45–47) of the case vignettes; with shortened life expectancy, this proportion increased to 90% (95CI% 89–90). Advice to stop was more frequent in case vignettes without CVD compared to those with CVD (ORadj 13.8, 95%CI 12.6–15.1), with side effects compared to without ORadj 1.62 (95%CI 1.5–1.7) and with frailty (ORadj 4.1, 95%CI 3.8–4.4) compared to without. Shortened life expectancy increased advice to stop (ORadj 50.7, 95%CI 45.5–56.4) and was the strongest predictor for GP advice to stop, ranging across countries from 30% (95%CI 19–42) to 98% (95% CI 96–99). Conclusions: The absence of CVD, the presence of statin-related side effects, and frailty were all independently associated with GPs’ advice to stop statins in patients aged > 80 years. Overall, and within all countries, cancer-related short life expectancy was the strongest independent predictor of GPs’ advice to stop statins. © 2019, The Author(s).

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13514Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1007/s11606-018-4795-xYayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorvan der Ploeg, Milly A.
dc.contributor.authorStreit, Sven
dc.contributor.authorAchterberg, Wilco P.
dc.contributor.authorBeers, Erna
dc.contributor.authorBohnen, Arthur M.
dc.contributor.authorBurman, Robert A.
dc.contributor.authorCollins, Claire
dc.contributor.authorFranco, Fabio G.
dc.contributor.authorGerasimovska-Kitanovska, Biljana
dc.contributor.authorGintere, Sandra
dc.contributor.authorGomez Bravo, Raquel
dc.contributor.authorHoffmann, Kathryn
dc.contributor.authorIftode, Claudia
dc.contributor.authorPeštić, Sanda Kreitmayer
dc.contributor.authorKoskela, Tuomas H.
dc.contributor.authorKurpas, Donata
dc.contributor.authorMaisonneuve, Hubert
dc.contributor.authorMallen, Christan D.
dc.contributor.authorMerlo, Christoph
dc.contributor.authorMueller, Yolanda
dc.contributor.authorMuth, Christiane
dc.contributor.authorPetrazzuoli, Ferdinando
dc.contributor.authorRodondi, Nicolas
dc.contributor.authorRosemann, Thomas
dc.contributor.authorSattler, Martin
dc.contributor.authorSchermer, Tjard
dc.contributor.authorŠter, Marija Petek
dc.contributor.authorŠvadlenková, Zuzana
dc.contributor.authorTatsioni, Athina
dc.contributor.authorThulesius, Hans
dc.contributor.authorTkachenko, Victoria
dc.contributor.authorTorzsa, Péter
dc.contributor.authorTsopra, Rosy
dc.contributor.authorTuz, Canan
dc.contributor.authorVaes, Bert
dc.contributor.authorViegas, Rita P. A.
dc.contributor.authorVinker, Shlomo
dc.contributor.authorWallis, Katharine A.
dc.contributor.authorZeller, Andreas
dc.contributor.authorGussekloo, Jacobijn
dc.contributor.authorPoortvliet, Rosalinde K. E.
dc.date.accessioned2026-10-18T20:28:20.961529161Z
dc.date.available2026-10-18T20:28:20.961529161Z
dc.date.issued2019
dc.description.abstractBackground: Statins are widely used to prevent cardiovascular disease (CVD). With advancing age, the risks of statins might outweigh the potential benefits. It is unclear which factors influence general practitioners’ (GPs) advice to stop statins in oldest-old patients. Objective: To investigate the influence of a history of CVD, statin-related side effects, frailty and short life expectancy, on GPs’ advice to stop statins in oldest-old patients. Design: We invited GPs to participate in this case-based survey. GPs were presented with 8 case vignettes describing patients > 80 years using a statin, and asked whether they would advise stopping statin treatment. Main Measures: Cases varied in history of CVD, statin-related side effects and frailty, with and without shortened life expectancy (< 1 year) in the context of metastatic, non-curable cancer. Odds ratios adjusted for GP characteristics (ORadj) were calculated for GPs’ advice to stop. Key Results: Two thousand two hundred fifty GPs from 30 countries participated (median response rate 36%). Overall, GPs advised stopping statin treatment in 46% (95%CI 45–47) of the case vignettes; with shortened life expectancy, this proportion increased to 90% (95CI% 89–90). Advice to stop was more frequent in case vignettes without CVD compared to those with CVD (ORadj 13.8, 95%CI 12.6–15.1), with side effects compared to without ORadj 1.62 (95%CI 1.5–1.7) and with frailty (ORadj 4.1, 95%CI 3.8–4.4) compared to without. Shortened life expectancy increased advice to stop (ORadj 50.7, 95%CI 45.5–56.4) and was the strongest predictor for GP advice to stop, ranging across countries from 30% (95%CI 19–42) to 98% (95% CI 96–99). Conclusions: The absence of CVD, the presence of statin-related side effects, and frailty were all independently associated with GPs’ advice to stop statins in patients aged > 80 years. Overall, and within all countries, cancer-related short life expectancy was the strongest independent predictor of GPs’ advice to stop statins. © 2019, The Author(s).
dc.identifier.doi10.1007/s11606-018-4795-x
dc.identifier.endpage1757
dc.identifier.issn0884-8734
dc.identifier.issue9
dc.identifier.pmcidPMC6711940
dc.identifier.pmid30652277
dc.identifier.scopus2-s2.0-85060148045
dc.identifier.startpage1751
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13514
dc.identifier.volume34
dc.language.isoen
dc.publisherSpringer New York LLC
dc.relation.ispartofJournal of General Internal Medicine
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectcardiovascular diseases
dc.subjectclinical decision-making
dc.subjectdrug therapy
dc.subjectgeneral practitioners
dc.subjecthydroxymethylglutaryl-CoA reductase inhibitors
dc.subjectpalliative care
dc.subjectAged, 80 and over
dc.subjectCase-Control Studies
dc.subjectFemale
dc.subjectHumans
dc.subjectInternationality
dc.subjectLife Expectancy
dc.subjectMale
dc.subjectPractice Patterns, Physicians'
dc.subjectSurveys and Questionnaires
dc.subjectWithholding Treatment
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitor
dc.subjectaged
dc.subjectArticle
dc.subjectcardiovascular disease
dc.subjectclinical article
dc.subjectclinical feature
dc.subjectclinical practice
dc.subjectcontrolled study
dc.subjectcounseling
dc.subjectdrug induced disease
dc.subjectfrailty
dc.subjectgeneral practitioner
dc.subjectgeriatric patient
dc.subjecthuman
dc.titlePatient Characteristics and General Practitioners’ Advice to Stop Statins in Oldest-Old Patients: a Survey Study Across 30 Countries
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus16
rdl.departmentErzincan University Family Medicine Department, Erzincan, Turkey.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexPUBMED